EvoXRare AI-Assisted Interpretation of Emergency Chest Radiographs (CXR-AI-RCT)
EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial
Chest radiography is widely used in emergency departments, resuscitation rooms, intensive care units, and other acute-care settings. Clinically important abnormalities may be missed because findings are subtle, uncommon, obscured by overlapping anatomy, or encountered under high workload. This pragmatic randomized trial evaluates whether EvoXRare, an artificial intelligence system that provides a draft chest radiograph report and high-risk alerts for uncommon or clinically important abnormalities, reduces clinically important diagnostic misses compared with routine physician interpretation alone. Approximately 70,000 adults will be randomized 1:1 across 15-20 hospitals in China. The primary endpoint is the patient-level rate of clinically important abnormalities present on the reference standard but not reported in the initial clinical interpretation. Key secondary outcomes include detection of rare or easily missed findings, time to recognition of critical abnormalities, report turnaround time, false-positive alerts, additional imaging, recall/communication events, and selected short-term clinical outcomes.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a nationwide, multicenter, prospective, parallel-group, superiority randomized controlled trial with individual participant-level 1:1 allocation and blinded central endpoint adjudication. Eligible participants are adults undergoing clinically indicated chest radiography in emergency or critical-care settings. Only one index radiograph encounter per participant contributes to the primary randomized analysis.
In the control arm, physicians interpret the chest radiograph using the participating hospital's usual workflow without access to EvoXRare trial output. In the intervention arm, EvoXRare processes the same image on an independent AI workstation and provides a pre-generated report and/or high-risk prompts. The physician must review the original image, verify or edit the AI output, and remains responsible for the final report and all clinical communication. Both arms retain routine senior review and local critical-result procedures.
The AI model version, weights, preprocessing, thresholds, supported finding set, and report format are frozen before formal enrollment. No online learning or outcome-driven recalibration occurs during the randomized trial. If AI processing fails or images do not meet technical requirements, clinical care proceeds without delay and the participant remains in the assigned group for intention-to-treat analysis.
The reference standard is established by a blinded adjudication process using the index radiograph together with clinically available follow-up information, which may include subsequent CT, ultrasound, pathology, surgery, laboratory findings, clinical course, discharge diagnosis, or follow-up imaging. Adjudicators do not use the randomized assignment or EvoXRare output when determining whether a prespecified abnormality was present on the index radiograph.
The trial is designed primarily to test clinical diagnostic performance and workflow impact, not to retrain the AI system. It specifically emphasizes uncommon, high-consequence, and easily missed chest radiograph findings while also evaluating overall report quality and efficiency.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Xiaoyu Han, PhD
- 電話番号:+86 18202771604
- メール:xiaoyuhan1123@163.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 years or older.
- Undergoing a clinically indicated chest radiograph in a participating emergency department, resuscitation room, intensive care unit, or other prespecified acute/critical-care setting.
- Chest radiograph is technically accessible to the study workflow before or during routine clinical interpretation.
- The participant has not previously been randomized in this trial, unless the final protocol explicitly permits a separate recurrent-encounter analysis that does not enter the primary endpoint.
- Consent or ethics-approved waiver/alteration of consent is satisfied according to the activated site protocol.
Exclusion Criteria:
- Age younger than 18 years.
- Image is missing, corrupted, or technically non-diagnostic to a degree that prevents clinical interpretation.
- Radiograph was obtained solely for research rather than clinical care.
- AI processing cannot be initiated because the image format or transfer route is outside the locked system specification; such cases may be recorded in screening logs but are not randomized unless the protocol allows post-randomization technical failure.
- Prior randomization of the same participant in this trial for the primary participant-level analysis.
- Any local legal, ethical, or institutional restriction that prevents study participation or required data use.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:EvoXRare AI-Assisted Chest Radiograph Interpretation.
Usual chest radiograph interpretation plus access to EvoXRare-generated draft report and high-risk prompts. The physician reviews the original image, accepts/rejects/edits AI suggestions, submits the final report, and follows local critical-result communication procedures. |
EvoXRare is an artificial intelligence software system that analyzes chest radiographs and provides draft reports and high-risk prompts to the interpreting physician. The physician reviews the original images and AI outputs and accepts, rejects, or edits the suggestions before finalizing the radiology report. |
|
介入なし:No Intervention / Active usual-care comparator: Standard Chest Radiograph Interpretation.
Routine physician interpretation according to the participating hospital's usual workflow, without access to EvoXRare trial output. Routine nontrial tools already in use may continue only if documented before site activation and applied consistently. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient-Level Clinically Important Abnormality Miss Rate on the Index Chest Radiograph
時間枠:From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).
|
Proportion of randomized participants with at least one prespecified clinically important abnormality (Category A or B) judged present on the reference standard but absent from the initial finalized chest radiograph report produced under the assigned strategy. |
From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).
|
協力者と研究者
スポンサー
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- WHUH-CXR-AI-RCT-2026-11
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Yes, through controlled access subject to compatible consent/ethics approval and institutional authorization.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。